Based on these results, the combination of trastuzumab with carboplatin and paclitaxel is recommend for HER2-positive uterine serous carcinoma patients with stage III/IV disease as a primary therapy or for recurrent disease, whereas it is recommended as a category 2 option for HER2-positive carcinosarcoma in both disease settings [139]. Here, ERBB2 is linked to endometrial serous adenocarcinoma.